Small hydrophobic protein of respiratory syncytial virus as a novel vaccine antigen

Immunotherapy

Volumn 7, Issue 3, 2015, Pages 203-206

  Schepens, Bert ^a,b   Schotsaert, Michael ^c   Saelens, Xavier ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

human respiratory syncytial virus; small hydrophobic protein; vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SMALL HYDROPHOBIC PROTEIN; UNCLASSIFIED DRUG; ONCOPROTEIN; SMALL HYDROPHOBIC PROTEIN, VIRUS; VIRUS ANTIGEN;

DRUG EFFICACY; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNE RESPONSE; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; T LYMPHOCYTE; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; HUMAN; IMMUNE EVASION; IMMUNOLOGY; LUNG ALVEOLUS MACROPHAGE; NEWBORN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIROLOGY; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, VIRAL; HUMANS; IMMUNE EVASION; INFANT, NEWBORN; MACROPHAGES, ALVEOLAR; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; RETROVIRIDAE PROTEINS, ONCOGENIC; VIRUS REPLICATION;

EID: 84925753643     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.11     Document Type: Review

References (34)

1. Nair H, Nokes DJ, Gessner BD et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375(9725), 1545-1555 (2010).
2. Liesman RM, Buchholz UJ, Luongo CL et al. RSV-encoded NS2 promotes epithelial cell shedding and distal airway obstruction. J. Clin. Invest. 124(5), 2219-2233 (2014).
3. Welliver TP, Reed JL, Welliver RC Sr. Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases. Pediatr. Infect. Dis. J. 27(10 Suppl.), S92-S96 (2008).
4. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140(6), 543-546 (1986).
5. Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin. Infect. Dis. 33(6), 792-796 (2001).
6. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352(17), 1749-1759 (2005).
7. Espinoza JA, Bohmwald K, Cespedes PF, Riedel CA, Bueno SM, Kalergis AM. Modulation of host adaptive immunity by hRSV proteins. Virulence 5(7), 740-751 (2014).
8. Wright PF, Gruber WC, Peters M et al. Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. J. Infect. Dis. 185(8), 1011-1018 (2002).
9. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163(4), 693-698 (1991).
10. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 21(24), 3479-3482 (2003).
11. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102(3 Pt 1), 531-537 (1998).
12. Walsh EE, Hruska J. Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J. Virol. 47(1), 171-177 (1983).
13. Mclellan JS, Chen M, Joyce MG et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342(6158), 592-598 (2013).
14. Zhang W, Choi Y, Haynes LM et al. Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J. Virol. 84(2), 1148-1157 (2010).
15. Rixon HW, Brown G, Aitken J, McDonald T, Graham S, Sugrue RJ. The small hydrophobic (SH) protein accumulates within lipid-raft structures of the golgi complex during respiratory syncytial virus infection. J. Gen. Virol. 85(Pt 5), 1153-1165 (2004).
16. Collins PL, Mottet G. Membrane orientation and oligomerization of the small hydrophobic protein of human respiratory syncytial virus. J. Gen. Virol. 74(Pt 7), 1445-1450 (1993).
17. Carter SD, Dent KC, Atkins E et al. Direct visualization of the small hydrophobic protein of human respiratory syncytial virus reveals the structural basis for membrane permeability. FEBS Lett. 584(13), 2786-2790 (2010).
18. Fuentes S, Tran KC, Luthra P, Teng MN, He B. Function of the respiratory syncytial virus small hydrophobic protein. J. Virol. 81(15), 8361-8366 (2007).
19. Triantafilou K, Kar S, Vakakis E, Kotecha S, Triantafilou M. Human respiratory syncytial virus viroporin SH: a viral recognition pathway used by the host to signal inflammasome activation. Thorax 68(1), 66-75 (2013).
20. Whitehead SS, Bukreyev A, Teng MN et al. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J. Virol. 73(4), 3438-3442 (1999).
21. Akerlind-Stopner B, Hu A, Mufson MA, Utter G, Norrby E. Antibody responses of children to the C-terminal peptide of the SH protein of respiratory syncytial virus and the immunological characterization of this protein. J. Med. Virol. 40(2), 112-120 (1993).
22. Schepens B, Sedeyn K, Vande Ginste L et al. Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein. EMBO Mol. Med. 6(11), 1436-1454 (2014).
23. Bukreyev A, Whitehead SS, Murphy BR, Collins PL. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J. Virol. 71(12), 8973-8982 (1997).
24. Boyoglu-Barnum S, Gaston KA, Todd SO et al. A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. J. Virol. 87(20), 10955-10967 (2013).
25. Corbeil S, Seguin C, Trudel M. Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus long strain following passive immunization with monoclonal antibody 18A2B2. Vaccine 14(6), 521-525 (1996).
26. Crowe JE, Jr, Murphy BR, Chanock RM, Williamson RA, Barbas CF, 3rd, Burton DR. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc. Natl Acad. Sci. USA 91(4), 1386-1390 (1994).
27. Schepens B, Ibanez LI, De Baets S et al. Nanobodies(R) specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J. Infect. Dis. 204(11), 1692-1701 (2011).
28. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcgamma receptors in dendritic cells and macrophages. Nat. Rev. Immunol. 14(2), 94-108 (2014).
29. Bukreyev A, Yang L, Fricke J et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J. Virol. 82(24), 12191-12204 (2008).
30. Reed JL, Brewah YA, Delaney T et al. Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. J. Infect. Dis. 198(12), 1783-1793 (2008).
31. El Bakkouri K, Descamps F, De Filette M et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186(2), 1022-1031 (2011).
32. Ramos EL, Mitcham JL, Koller TD et al. Efficacy and safety of treatment with an anti-M2e monoclonal antibody in experimental human influenza. J. Infect. Dis. pii: jiu539 (2014) (Epub ahead of print).
33. Bagga B, Woods CW, Veldman TH et al. Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals. Antiviral Ther. 18(6), 785-791 (2013).
34. Wright PF, Karron RA, Belshe RB et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182(5), 1331-1342 (2000).